Neprilysin gene transfer reduces human amyloid pathology in transgenic mice.

  • Marr R
  • Rockenstein E
  • Mukherjee A
  • et al.
ISSN: 1529-2401
N/ACitations
Citations of this article
102Readers
Mendeley users who have this article in their library.

Abstract

The degenerative process of Alzheimer's disease is linked to a shift in the balance between amyloid-beta (Abeta) production, clearance, and degradation. Neprilysin has recently been implicated as a major extracellular Abeta degrading enzyme in the brain. However, there has been no direct demonstration that neprilysin antagonizes the deposition of amyloid-beta in vivo. To address this issue, a lentiviral vector expressing human neprilysin (Lenti-Nep) was tested in transgenic mouse models of amyloidosis. We show that unilateral intracerebral injection of Lenti-Nep reduced amyloid-beta deposits by half relative to the untreated side. Furthermore, Lenti-Nep ameliorated neurodegenerative alterations in the frontal cortex and hippocampus of these transgenic mice. These data further support a role for neprilysin in regulating cerebral amyloid deposition and suggest that gene transfer approaches might have potential for the development of alternative therapies for Alzheimer's disease.

Cite

CITATION STYLE

APA

Marr, R. A., Rockenstein, E., Mukherjee, A., Kindy, M. S., Hersh, L. B., Gage, F. H., … Masliah, E. (2003). Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience, 23(6), 1992–6. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12657655

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free